Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical expectations. Regulators are mandating transparency in AI models used for drug testing and development.
- What Drives eConsent Adoption? Reasons May Be Different Than You Think
- Unlocking Next Generation Clinical Trials Through Data Sharing & Tech-Driven Approaches
- Meaningful Industry Change Means Balancing Tech And Human Touch
- What Can Digital Patient Twins Do For Clinical Research?
- ICH E6(R3) And Defining What Is Critical To TMF Quality
- A Structured Approach To Regulatory Information Management Vendor Selection
- 3 Tips For Selecting Your eTMF Platform
- eCOA Solutions: Trends, Benefits, & Buying In 2024
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Simply Digital: Trial Technologies Help Reduce Oncology's Burden
Oncology trials are notorious for presenting participants and sites with many challenges. With the FDA having put its support behind digital tools, learn how they make oncology trials easier for everyone.
-
7 eCOA Design Recommendations: Insights From Sites And CRAs
Signant joined a group of C-Path members including other eCOA solution providers, sponsors, and regulators for a GBTI project that revealed several opportunities to improve eCOA usability and flexibility.
-
The Power Of Adaptive Learning
Delve into the details of this approach to training, which addresses common complaints, and how it holds promise for enhancing the efficiency and performance of clinical research staff.
-
Navigating Wearable Integration: Key Operational Considerations
Explore wearable devices' transformative potential and innovative capabilities for data collection, patient monitoring, and endpoint measurement.
-
The TMF Trifecta: Finding Balance In An Era Of Constant Change
In this article, discover TMF through the operational framework of people, process, and technology and how these factors affect stakeholders.
-
FDA Releases Updated Draft Guidance On Decentralized Clinical Trials
Take a closer look at the FDA's draft guidance on designing and implementing DCTs, notably remote trial visits, the use of digital health technologies, institutional review board oversight, and more.
-
Enhancing Oncology Trials With Clinical Platform Solutions
This example involves a top 10 pharmaceutical company and explores how they were able to improve oncology trial efficiency, safety, patient experience, and more using a platform approach.
-
The Future Of EDC Systems
Gain insight from EDC users in sponsor organizations and CROs regarding anticipated trends in the next two years and how EDC systems can align with decentralized clinical trials.
-
Medical Center Offers Best-In-Class Participant Experience And Alleviates Administrative Burdens
Discover how UH Cleveland Medical Center improved participant satisfaction and efficiency by streamlining processes and eliminating administrative hurdles.
-
Improve Clinical Trial Management With Automated CTMS Tools
Uncover how advancements in clinical trial management systems signify a significant shift towards more streamlined and effective clinical trial management, ultimately enhancing the quality and pace of medical research endeavors.
FREE E-BOOK
![ISR Reports perspectives snip thumb ISR Reports perspectives snip thumb](https://vertassets.blob.core.windows.net/image/51d6e26c/51d6e26c-3f90-494a-8897-e2ef3589e27d/isr_reports_perspectives_snip_thumb.jpg)
ISR Reports recently conducted research to understand the pharma industry’s experiences with clinical technology providers. Based on their findings, they created Industry Perspectives On Clinical Technologies, an e-book that discusses characteristics to consider when selecting an IRT provider, why sponsors use more than one CTMS solution, the future of EDC, and more.
Read The E-book!